<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04687657</url>
  </required_header>
  <id_info>
    <org_study_id>XJTU1AF-CRF-2020-016</org_study_id>
    <nct_id>NCT04687657</nct_id>
  </id_info>
  <brief_title>Umbilical Cord Blood Transfusion in Consolidation Therapy of Elderly Patients With Acute Myeloid Leukemia</brief_title>
  <official_title>Application of Umbilical Cord Blood Transfusion in Consolidation Therapy of Elderly Patients With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      After complete remission, elderly AML patients cannot tolerate hematopoietic stem cell&#xD;
      transplantation and standard-dose consolidation chemotherapy, and the 5-year survival rate is&#xD;
      around 10%. Therefore, it is necessary to explore treatment strategy that can support&#xD;
      chemotherapy or improve immunity. Umbilical cord blood is rich in hematopoietic stem cells&#xD;
      and immune cells. However,Cord blood transplantation for adults is still being explored. The&#xD;
      application of cord blood in supportive treatment can be actively explored. Cord blood has&#xD;
      low immunogenicity and is unlikely to cause Graft versus host disease (GVHD), and the&#xD;
      infusion is relatively safe. The Department of Hematology of Shanghai Ruijin Hospital has&#xD;
      conducted a related phase II clinical study, and found that cord blood transfusion reduced&#xD;
      the chance of infection and increased the 2-year survival. Our subject is a prospective&#xD;
      single-arm clinical study. It is planned to recruit 20 elderly AML patients to explore&#xD;
      whether the application of cord blood infusion can further improve the prognosis of patients&#xD;
      during their consolidation chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      20 elderly AML patients who achieved complete remission (CR) after induction chemotherapy&#xD;
      will be enrolled in this study. Baseline data are collected and informed consents are signed&#xD;
      before consolidation chemotherapy. At the same time, HLA typing test is carried out, and the&#xD;
      corresponding cord blood is matched from the cord blood bank. During the consolidation&#xD;
      chemotherapy stage, the cord blood transfusion is given twice (interval of 1 month) to&#xD;
      support treatment. On the first day after umbilical cord blood transfusion, the proportion of&#xD;
      NK cells in peripheral blood are detected. If it is less than 20%, the NK cells are activated&#xD;
      by subcutaneous injection of recombinant human interleukin-2 (rhIL-2) on the second day after&#xD;
      infusion. The treatment effects are continuously monitored and followed up regularly after&#xD;
      treatment.The intend of this trial is to explore whether cord blood transfusion in the&#xD;
      consolidation phase can further reduce the recurrence rate of AML and improve prognosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year Overall survival</measure>
    <time_frame>2-years</time_frame>
    <description>the overall survival rate of enrolled patients at the end of 2 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2-year Disease-free survival</measure>
    <time_frame>2-years</time_frame>
    <description>DFS is measured from the date when CR is achieved. And the end includes death or relapse.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Leukemia, Myelomonocytic, Acute</condition>
  <arm_group>
    <arm_group_label>cord blood transfusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The arm that will receive the target treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>umbilical cord blood</intervention_name>
    <description>During the consolidation chemotherapy stage, the umbilical cord blood transfusion is given twice (interval of 1 month) to support treatment. On the first day after umbilical cord blood transfusion, the proportion of NK cells in peripheral blood is detected. If it is less than 20%, the NK cells sre activated by subcutaneous injection of recombinant human interleukin-2 (rhIL-2) on the second day after infusion.</description>
    <arm_group_label>cord blood transfusion</arm_group_label>
    <other_name>cord blood</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥60 years&#xD;
&#xD;
          -  Patients with primary AML diagnosed in accordance with the &quot;Adult Acute Myeloid&#xD;
             Leukemia (Non-Acute Promyelocytic Leukemia) Chinese Diagnosis and Treatment Guidelines&#xD;
             (2017 Edition)&quot;, who achieved CR after induction chemotherapy&#xD;
&#xD;
          -  Normal heart function , Ejection fraction ≥ 50%&#xD;
&#xD;
          -  Normal liver function with ALT and AST ≤ 2.5 times the upper limit of normal value,&#xD;
             bilirubin ≤ 2 times the upper limit of normal value&#xD;
&#xD;
          -  Normal kidney function with blood creatinine ≤ 3.0 mg/dL (≤ 260 µmol/L)&#xD;
&#xD;
          -  Voluntarily signed an informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Combined with severe infection&#xD;
&#xD;
          -  Combined with other malignant tumors&#xD;
&#xD;
          -  Other patients deemed unsuitable to be tested by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>huaiyu Wang, doctor</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital Xi'an Jiaotong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>huaiyu Wang, doctor</last_name>
    <phone>0086-18991232410</phone>
    <email>whymed@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>sha Gong, doctor</last_name>
    <phone>0086-18710720955</phone>
    <email>314621649@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The first affiliated hospital of Xi'an jiaotong university</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>huaiyu Wang</last_name>
      <phone>085-18991232410</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xi'anJiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>huaiyu Wang</last_name>
      <phone>0086-18991232410</phone>
      <email>whymed@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015 Sep 17;373(12):1136-52. doi: 10.1056/NEJMra1406184. Review.</citation>
    <PMID>26376137</PMID>
  </results_reference>
  <results_reference>
    <citation>Li X, Dong Y, Li Y, Ren R, Wu W, Zhu H, Zhang Y, Hu J, Li J. Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study. BMC Cancer. 2019 Aug 20;19(1):819. doi: 10.1186/s12885-019-5975-8.</citation>
    <PMID>31429724</PMID>
  </results_reference>
  <results_reference>
    <citation>Dolstra H, Roeven MWH, Spanholtz J, Hangalapura BN, Tordoir M, Maas F, Leenders M, Bohme F, Kok N, Trilsbeek C, Paardekooper J, van der Waart AB, Westerweel PE, Snijders TJF, Cornelissen J, Bos G, Pruijt HFM, de Graaf AO, van der Reijden BA, Jansen JH, van der Meer A, Huls G, Cany J, Preijers F, Blijlevens NMA, Schaap NM. Successful Transfer of Umbilical Cord Blood CD34(+) Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients. Clin Cancer Res. 2017 Aug 1;23(15):4107-4118. doi: 10.1158/1078-0432.CCR-16-2981. Epub 2017 Mar 9.</citation>
    <PMID>28280089</PMID>
  </results_reference>
  <results_reference>
    <citation>Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013 Jul 25;122(4):491-8. doi: 10.1182/blood-2013-02-453175. Epub 2013 May 14. Review.</citation>
    <PMID>23673863</PMID>
  </results_reference>
  <results_reference>
    <citation>Stringaris K, Sekine T, Khoder A, Alsuliman A, Razzaghi B, Sargeant R, Pavlu J, Brisley G, de Lavallade H, Sarvaria A, Marin D, Mielke S, Apperley JF, Shpall EJ, Barrett AJ, Rezvani K. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica. 2014 May;99(5):836-47. doi: 10.3324/haematol.2013.087536. Epub 2014 Jan 31.</citation>
    <PMID>24488563</PMID>
  </results_reference>
  <results_reference>
    <citation>Mehta RS, Shpall EJ, Rezvani K. Cord Blood as a Source of Natural Killer Cells. Front Med (Lausanne). 2016 Jan 5;2:93. doi: 10.3389/fmed.2015.00093. eCollection 2015. Review.</citation>
    <PMID>26779484</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 27, 2020</study_first_submitted>
  <study_first_submitted_qc>December 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia, Myelomonocytic, Acute</keyword>
  <keyword>Umbilical cord blood transfusion</keyword>
  <keyword>treatment effect</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No sharing plan</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

